{
    "nct_id": "NCT05800600",
    "official_title": "Iron Replacement to Reduce Anemia During Neoadjuvant Chemotherapy",
    "inclusion_criteria": "* Male or female patients > 18 years\n* Patients undergoing neoadjuvant chemotherapy, including radiation and/or immunotherapy, with intent for curative surgical resection for breast, thoracic, gastrointestinal (GI) or genitourinary (GU) malignancies.\n* Anemia defined as Hgb <10.5 g/dL during chemotherapy.\n* Iron storage levels of ferritin <500 ng/mL and iron saturation <35%\n* Ability to understand and willingness to sign a written informed consent and HIPAA consent document\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Diagnosis of anemia at the time of cycle 1 day 1 of neoadjuvant chemotherapy, Hgb < 11.0 g/dL, uncontrolled intercurrent illness including, but not limited to, ongoing active infection, symptomatic new/exacerbated congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements\n* Prior parenteral iron infusion in the past 4 weeks\n* The use of erythropoietin stimulating agents within 4 weeks unless chronic needs due to CKD\n* Concurrent systemic infection at the time of enrollment.\n* Known hypersensitivity to Iron sucrose\n* Pregnant or breast feeding. Refer to section 4.4 for further detail.\n* Anemia from another established etiology (i.e MDS, Myeloma)",
    "miscellaneous_criteria": ""
}